J&J Maintains Top Pharma Brand Ranking Despite Industry Downturn 7/6/2023

Takeda, F-star Sign Potential $1B Immuno-Oncology Agreement 7/6/2023

Sumitomo Cuts 62 Jobs in NYC Due to Company Consolidation 7/6/2023

Less Than Half of New Drug Approvals Add Therapeutic Value Over Existing Treatments: Study 7/6/2023

Keytruda Keeps Racking Up Approvals and Clinical Wins in 2023 7/6/2023

Editorial: Gen Z Works for the Money—And You Should, Too 7/6/2023

Today, the U.S. Food and Drug Administration is announcing the availability of a draft guidance with updated recommendations for good clinical practices (GCPs) aimed at modernizing the design and conduct of clinical trials, making them more agile without compromising data integrity or participant protections. The updates are intended to help pave the way for more efficient clinical trials to facilitate the development of medical products.

AbbVie (NYSE: ABBV) announced the New England Journal of Medicine (NEJM) published results from the pivotal Phase 3 clinical trials - U-EXCEL, U-EXCEED and U-ENDURE - evaluating upadacitinib (RINVOQ®) in adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to conventional therapy or a biologic agent.

ASCO Highlights 6/6/2023

In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma are on treatment without their cancer worsening. The finding suggests a possible new treatment option for people with the slow-growing but deadly brain tumor.

The team found the drug vorasidenib more than doubled progression-free survival in people with recurrent grade 2 glioma with IDH1 and IDH2 mutations.